Successful treatment of anemia in idiopathic myelofibrosis with recombinant human erythropoietin

Hans Carl Hasselbalch*, Nielsaage Tøffner Clausen, Bjarne Anker

*Corresponding author af dette arbejde

    Publikation: Bidrag til tidsskriftArtikelForskningpeer review

    Abstract

    Thirteen patients with idiopathic myelofibrosis (5 osteomyelosclerosis) were treated with recombinant human erythropoietin (rHuEpo) for transfusion-dependent anemia. All but 7 patients were concomitantly treated with alpha interferon, and 5 patients also received α interferon before the start of erythropoietin (EPO) treatment. All but two patients became transfusion independent. The highly positive results of the present study of transfusion-dependent patients with idiopathic myelofibrosis calls for further studies to delineate more precisely in larger series those patients who are likely to respond to rHuEpo.

    OriginalsprogEngelsk
    Sider (fra-til)92-99
    Antal sider8
    TidsskriftAmerican Journal of Hematology
    Vol/bind70
    Udgave nummer2
    DOI
    StatusUdgivet - 4 jun. 2002

    Fingeraftryk

    Udforsk hvilke forskningsemner 'Successful treatment of anemia in idiopathic myelofibrosis with recombinant human erythropoietin' indeholder.

    Citationsformater